BP
IRWD icon

Ballentine Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Ballentine Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,541
Closed -$88.7K – 919
2024
Q3 		$88.7K Buy
+21,541
New +$116K ﹤0.01% 810

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Ballentine Partners's IRWD Position: Q4 2024 in Review

Ballentine Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2024, closing a stake of 21,541 shares — an estimated $88.7K sold.

Ballentine Partners first reported a position in IRWD in Q3 2024 and held it in 1 quarter. The position peaked at $88.7K in Q3 2024. 223 funds tracked by Wall St. Rank hold IRWD as of Q4 2024.

  • Ballentine Partners reported no remaining Ironwood Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Ballentine Partners sold 21,541 Ironwood Pharmaceuticals shares in Q4 2024, an estimated $88.7K.
  • Ballentine Partners first reported a position in Ironwood Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Ballentine Partners's Ironwood Pharmaceuticals position peaked at $88.7K in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2024.

Based on Ballentine Partners's 13F filing for Q4 2024, filed 16 Jan 2025.